ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009

SAN DIEGO—(BUSINESS WIRE)—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the BIO CEO & InvestorConference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. EasternTime at The Waldorf=Astoria Hotel in New York City.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through February 24, 2009.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is focused on developing aportfolio of its four most advanced product candidates, includingpimavanserin in Phase III for Parkinson’s disease psychosis, a productcandidate in Phase II for chronic pain and a product candidate in PhaseI for glaucoma, both in collaboration with Allergan, and ACP-106 inIND-track development. All of the product candidates in ACADIA’spipeline emanate from discoveries made using its proprietary drugdiscovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, InvestorRelations
Thomas H. Aasen, Vice President and ChiefFinancial Officer
858-558-2871